United Therapeutics price target lowered to $345 from $375 at Argus

Argus lowered the firm’s price target on United Therapeutics (UTHR) to $345 from $375 but keeps a Buy rating on the shares. The company continues to advance its organ development and transplant program, recently announcing the FDA clearance of its Investigational New Drug application to initiate a clinical study of the company’s investigational UKidney, a xenokidney from a pig with 10 gene edits, and given the strong performance of the company’s Tyvaso franchise, as well as other products in the company’s portfolio, the firm sees continued upside in the stock price over the next year, the analyst tells investors in a research note.